Neurosteer started a clinical study at Langone Hospital, NYU with Prof. Leigh Charvet, on quantifying the effect of tDCS on Multiple Sclerosis (MS) patients. MS patients receive a frontal lobe stimulation to improve their cognition. Such stimulation is not always effective, and often patients receive 20 stimulation sessions to discover at the end that there was no effect. Neurosteer’s device will assess the effectiveness of the stimulation after one session and this will be correlated with the effect after 20 sessions. Such an assessment can provide an indication of the effectiveness of the treatment.